ClinicalTrials.Veeva

Menu
S

Southern Therapy and Advanced Research, LLC | Jackson, MS

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Obeticholic Acid
MGL-3196
Cilofexor
Resmetirom
RBV
Semaglutide
K-877-ER
UDCA
OCA
DUR-928

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 26 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling
Non-Alcoholic Fatty Liver Disease
Drug: Resmetirom

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or red...

Active, not recruiting
NASH - Nonalcoholic Steatohepatitis
Procedure: Liver Biopsy
Drug: MGL-3196

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Placebo
Drug: Etrasimod

The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching)...

Enrolling
Primary Sclerosing Cholangitis
Drug: Volixibat
Drug: Placebo

The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Prim...

Enrolling
Hepatic Impairment
Compensated Cirrhosis
Drug: Seladelpar 10 mg
Drug: Seladelpar 10 mg or less

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Active, not recruiting
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firso...

Active, not recruiting
Nonalcoholic Steatohepatitis
Drug: Cilofexor (CILO)/Firsocostat (FIR)
Drug: PTM SEMA

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatoh...

Enrolling
NASH
Drug: K-877-ER
Drug: Placebo

Trial sponsors

Exact Sciences Corporation logo
Gilead Sciences logo
I
Madrigal Pharmaceuticals logo
CymaBay Therapeutics logo
T
A
D
G
Ionis Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems